Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog)
Phoebe Clark1, Paul Rosenberg1, Esther S Oh1
1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Methylphenidate shows promise in treating cognitive dysfunction following COVID-19 infection. This study found improvements in memory and verbal fluency in patients with long COVID, suggesting a potential therapeutic option.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Cognitive dysfunction is a significant complication of SARS-CoV-2 infection, contributing to long COVID morbidity.
- No proven interventions currently exist for post-COVID cognitive dysfunction (PCCD).
- Methylphenidate, a psychostimulant, may improve cognition by enhancing noradrenergic and dopaminergic pathways.
More Related Videos
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
10:32Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Alzheimer's Disease: Treatment
Antidepressant Drugs: MAOIs and Other Agents
